Study evaluating lutetium (¹⁷⁷Lu) vipivotide tetraxetan in patients with progressive metastatic castration-resistant prostate cancer (mCRPC) with moderate or severe renal impairment or normal renal function

Patients with progressive metastatic castration-resistant prostate cancer, positive for prostate-specific membrane antigen (PSMA), with:
- Moderate renal impairment
- Severe renal impairment
- Normal renal function

Phase 1b/3 randomized, controlled, open-label trial comparing RYZ101 with standard treatment in patients with inoperable, advanced, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NET) expressing somatostatin receptors (SSTR+) that progressed after prior treatment with a ¹⁷⁷Lu-labeled somatostatin analogue (¹⁷⁷Lu-SSA)

Gastroenteropancreatic neuroendocrine tumors (GEP-NET)

Assessment of the ¹⁸F-florbetaben whole-body PET imaging diagnostic performance for the detection of cardiac and extracardiac sites of amyloid deposits in patients with amyloidosis

Amyloidosis

Non-inferiority Study of the Molecular Imaging of Dopamine Transporters Using [123I]-FP/CIT-SPECT and [¹⁸F] LBT-999-PET to Distinguish Between Parkinson's Disease and Essential Tremor

Parkinson's disease and essential tremor

A multicenter, open-label, non-randomized Phase 1/2 study to assess safety,tolerability, and imaging characteristics of [⁶⁸Ga]Ga-DPI-4452 and to assess safety, tolerability, and efficacy of [¹⁷⁷Lu]Lu-DPI-4452 in patients with unresectable locally advanced or metastatic solid tumors

Histologically or cytologically confirmed, unresectable locally advanced or metastatic solid tumors of:
- ccRCC: patients must have received at least one line containing TKI treatment and at least one line containing Immune Checkpoint Inhibitor treatment in metastatic setting, meaning at least two lines of treatment in metastatic setting; or
- PDAC: patients must have received at least one line of platinum- and/or gemcitabine-based regimen; or
- CRC: patients must have received at least one line of FOLFIRINOX or FOLFOX/FOLFIRI in two lines in combination with anti-VEGF or anti-EGFR

A multicenter, open-label, non-randomized Phase 1/2 study to assess safety,tolerability, and imaging characteristics of [⁶⁸Ga]Ga-DPI-4452 and to assess safety, tolerability, and efficacy of [¹⁷⁷Lu]Lu-DPI-4452 in patients with unresectable locally advanced or metastatic solid tumors

Histologically or cytologically confirmed, unresectable locally advanced or metastatic solid tumors of:
- ccRCC: patients must have received at least one line containing TKI treatment and at least one line containing Immune Checkpoint Inhibitor treatment in metastatic setting, meaning at least two lines of treatment in metastatic setting; or
- PDAC: patients must have received at least one line of platinum- and/or gemcitabine-based regimen; or
- CRC: patients must have received at least one line of FOLFIRINOX or FOLFOX/FOLFIRI in two lines in combination with anti-VEGF or anti-EGFR

Contribution of Cerebral ¹⁸F-DOPA PET-CT Scan in High-grade Recurrent Gliomas : a Monocentric Pilot Impact Study on the Practices of Defining Target Volumes Before RAdiotherapy

Glioma

Pilot study evaluating somatostatin receptor PET imaging to detect inflammatory phases of myocarditis

Myocarditis

Early feasibility study of somatostatin receptor PET imaging for the diagnosis of infective endocarditis

Infective endocarditis

Prospective multicenter study to evaluate the diagnostic performance of [¹⁸F]PSMA-1007 PET/CT imaging in patients with newly diagnosed high-risk or very high-risk prostate cancer

Patients with newly diagnosed prostate cancer for whom surgical removal of the prostate and pelvic lymph nodes is initially planned (radical prostatectomy with extended pelvic lymph node dissection [RP with EPLND])

A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of ¹⁷⁷Lu-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

Evaluation of the addition of Everolimus to ¹⁷⁷Lu-DOTATATE in the treatment of grades 2 and 3 refractory meningioma: a phase IIb clinical trial

Grade 2 and 3 refractory meningioma

Evaluation of a routine clinical dosimetry method using the VERITON-CT™ camera in patients treated with Lutathera [¹⁷⁷Lu-[DOTA0, Tyr3]-octreotate

Patients receiving Luthatera ® therapy

Optimized Imaging of Fibrosis and Intestinal Inflammation in Crohn's Disease

Crohn's disease

GATED cardiac analysis in patients with ⁶⁸GA-DOTATOC PET for oncological indications

Diagnostic or pre-therapeutic workup or follow-up of a neuroendocrine tumor

Pilot study to evaluate the stage of liver fibrosis using PET imaging of fibroblast activation protein (⁶⁸Ga-FAPI-46 PET/CT) in patients who have undergone biopsy for suspected or confirmed non-alcoholic steatohepatitis (NASH)

Metabolic dysfunction-associated Steatotic Liver Disease

Randomized controlled trial evaluating the efficacy of HYpnosis using a DEported method adapted to Nuclear Medicine versus hypnosis using a conventional method

Ericksonian hypnosis session given to patients during a scintigraphic or PET examination in a remote setting

Evaluation of diagnostic performances of ¹⁸F-FDOPA PET KInetics as biomarkers for the improvement of care of MRI Non-contrast enhanced Gliomas

Suspicion of Glioma with MRI non contrast enhanced

Interest of the combination of ultrasound with Ti-RADS score / dual tracer MIBI-Tc99m/Iodine-123 scintigraphy in the detection of malignancy of thyroid nodules (≥ 15 mm) classified Bethesda III or IV in cytopuncture

Thyroid nodules (≥ 15 mm) classified as Bethesda III or IV on cytopuncture

Contribution of MUltiparametric analysis in bone scintigraphy for the characterization of solitary bone lesions whose malignant origin cannot be excluded on conventional imaging

Patients with solitary bone lesions indeterminate on conventional imaging who are scheduled for biopsy or excision

Randomized phase III trial aiming to evaluate whether administration of ¹⁷⁷Lu-PSMA-617 could improve disease management in men with de novo metastatic hormone-sensitive prostate cancer who are poor responders to standard treatment

Patients with de novo metastatic hormone-sensitive prostate cancer with serum PSA ≥ 0.2 ng/mL, 6 to 8 months after initiation of systemic therapy for mHSPC (i.e., with an unsatisfactory response to systemic therapy) in the absence of evidence of disease progression (including rising PSA)

Diagnostic performance of SPECT/CT bone scan quantification prior to lumbar arthodesis surgery

People with back pain for at least 3 months (presumed to be due to degenerative discarthrosis or spondylolisthesis)

A prospective, post-authorization, multicenter, open-label, non-interventional registry study to evaluate the efficacy of TheraSphere® in clinical practice in France

Unresectable hepatocellular carcinoma (HCC)

An International Prospective Open-label, Randomized, Phase III Study comparing ¹⁷⁷Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

A prospective randomized phase ii study to assess the schemas of retreatment with lutathera® ([¹⁷⁷Lu]lu-dota-tate) in patients with new progression of intestinal well-differentiated neuroendocrine tumor

intestinal well-differentiated neuroendocrine tumor

A Phase I/II, open-label, multi-center study of [²²⁵Ac]Ac-PSMA-R2 in men with heavily pre-treated PSMA positive metastatic castration resistant prostate cancer (mCRPC) with or without prior ¹⁷⁷Lu-labelled PSMAtargeted radioligand therapy

pre-treated PSMA positive metastatic castration resistant prostate cancer (mCRPC)

¹⁸F-FDG PET/CT characterization of brain lesions in young subjects with sequelae of psycho-cognitive disorders in the aftermath of severe Covid-19

Sequelae of psycho-cognitive disorders following severe Covid-19

Evaluation of a 3D whole-body acquisition procedure using the CZT VERITON-CT™ camera: comparison with the standard 2D whole-body acquisition procedure combined with additional SPECT imaging in patients treated with iodine-131 for thyroid cancer

Thyroid cancer patients for whom multidisciplinary consultation meeting has validated iratherapy treatment

A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry,and Preliminary Activity of [¹⁷⁷Lu]Lu-FAP-2286 in Participants with an Advanced Solid Tumor

Solid tumors

A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [¹⁷⁷Lu]Lu-DFC413 and safety and imaging properties of [⁶⁸Ga]Ga-NNS309 in patients with solid tumors

Solid tumors:
- Locally advanced or metastatic PDAC,
- NSCLC,
- HR+/HER2- ductal and lobular breast cancer,
- Triple-negative breast cancer,
- CRC and soft tissue sarcoma